dirk g brockstedt dirk brockstedt phd svp research  development aduro biotech dirk g brockstedt is senior vice president of research and development and has more than  years of experience in the fields of immunology and oncology originating with his phd from stanford university he was the third employee in the original immunotherapy group at cerus corporation and later brought the technology to aduro biotech inc where he was instrumental in the development of both the liveattenuated and killed listeria strains and he led the development of the lead product crs prior to cerus corporation dr brockstedt spent  years at aventis in the immunotherapy and antiangiogenesis group developing novel therapies against cancer dr brockstedt is the author of  peerreviewed scientific articles and is a named inventor on  issued patents and several patent applications dr brockstedt received his ba in microbiology and immunology from the university of kiel germany he earned his phd jointly at the university of kiel and stanford university and he was a postdoctoral fellow at stanford university dirk brockstedt aduro biotech inc profile  biography  bloomberg feedback dirk brockstedt exec vpresearch  development aduro biotech inc career history exec vpresearch  development aduro biotech present senior vpresearch  dev aduro biotech  aduro biotech unknown aventis former show more website wwwadurocom corporate information address  heinz avenue berkeley ca  united states phone  fax  web url wwwadurocom from the web personal information education stanford university phd sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data dirk g brockstedt phd executive profile  biography  bloomberg july    am et biotechnology company overview of aduro biotech inc snapshotpeople  overviewboard memberscommittees executive profile dirk g brockstedt phdexecutive vice president of research and development aduro biotech incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industries background dr dirk g brockstedt phd has been an executive vice president of research and development at aduro biotech inc since march  dr brockstedt served as senior vice president of research and development at aduro biotech inc since september  dr brockstedt served as vice president of research and development at aduro biotech inc dr brockstedt has more than  years of experience in the fields of immunology and oncology he was the third employee in  the original vaccine group at cerus corporation and later brought the technology to aduro he was instrumental in the development of both the liveattenuated and killed listeria strains and he led the development of the lead product crs prior to cerus corporation dr brockstedt spent  years at aventis in the immunotherapy and antiangiogenesis group developing novel therapies against cancer he is the author of more than  peerreviewed scientific articles and is a named inventor on  issued patents and several patent applications he holds his phd from stanford universityread full background corporate headquarters  heinz avenueberkeley california united statesphone fax  board members memberships there is no board members memberships data available education phd stanford universityms christian albrechts universität kiel other affiliations stanford universitychristian albrechts universität kiel annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationj joseph kim phdceo president  directorinovio pharmaceuticals incmsteven w king ceo president director ceo of avid bioservices inc and president of avid bioservices inc peregrine pharmaceuticals inckmark r baker jdchief executive officer and directorprogenics pharmaceuticals inckeddie gray chief executive officer and directordynavax technologies corporationklaurence james neil cooper phd mdchief executive officerziopharm oncology incmcompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact aduro biotech inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close for full functionality of researchgate it is necessary to enable javascript here are the instructions how to enable javascript in your web browser please wait while we are validating your browser dirk brockstedt  aduro biotech inc  zoominfocom dirk brockstedt  aduro biotech inc  zoominfocom leadership  aduro biotech pioneering immunotherapy transforming lives leadership stephen t isaacs chairman president and ceo thomas w dubensky jr phd chief scientific officer natalie r sacks md chief medical officer gregory w schafer chief operating officer hans van eenennaam phd chief operational officer aduro biotech europe andrea van elsas phd chief scientific officer aduro biotech europe   dirk g brockstedt phd executive vice president research  development jennifer lew senior vice president finance quoc lenguyen senior vice president chemistry manufacturing and control blaine templeman executive vice president general counsel and secretary sylvia wheeler senior vice president corporate affairs and investor relations   michele devries vice president regulatory affairs celeste ferber vice president associate general counsel nancy kaplan vice president human resources and facility operations anne moon phd vice president project management aimee murphy vice president clinical development and operations justin skoble phd vice president technical operations liana wu vice president commercial stephen t isaacs chairman president and ceo stephen t isaacs has served as our chairman president and chief executive officer since  prior to aduro in  mr isaacs founded cerus corporation a biomedical products company that commercialized the intercept blood systems he served as president and chief executive officer of cerus from  to  prior to cerus mr isaacs founded and served as chief executive officer and president of hri associates and hri research both biotechnology companies focused on research and development he held a nonteaching faculty position in the department of chemistry at the university of california berkeley from  to  mr isaacs has published over  peerreviewed scientific articles and is an inventor on over  issued patents mr isaacs holds a ba degree in biochemistry from university of california berkeley and had graduate training in organic chemistry in the phd program in the department of chemistry at berkeley  thomas w dubensky jr phd chief scientific officer thomas w dubensky jr phd has served as our chief scientific officer since september  from  to  dr dubensky served as chief scientific officer of immune design where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms prior to this in  he cofounded and served as chief scientific officer of anza therapeutics a biotechnology company that was spun out from cerus corporation where he had served as vice president of research for the five years prior  during this time dr dubensky helped to develop vaccine platforms based on attenuated strains of listeria monocytogenes which serves as the technology basis for aduro’s ladd platform earlier in his career dr dubensky developed vaccine platforms based on alphaviruses adenoviruses retroviruseslentiviruses and plasmid dna at a number of biotechnology companies including viagene chiron corporation and onyx pharmaceuticals dr dubensky has coauthored more than  scientific papers and is an inventor on  issued us patents with multiple pending applications dr dubensky received his ba in bacteriology and immunology from the university of california berkeley and his phd at the university of colorado health sciences center  he conducted his postdoctoral fellowship at harvard medical school in the department of pathology natalie r sacks md chief medical officer natalie sacks md has served as our chief medical officer since september  prior to joining aduro dr sacks served as an advisor on development strategy for multiple firms previously she was vice president of clinical development at onyx pharmaceuticals acquired by amgen where she played a key role in the development and approval of kyprolis® an fdaapproved therapy for the treatment of relapsed or refractory multiple myeloma and in business development strategy prior to that she served as vice president of clinical research for exelixis where she directed the development of a portfolio of small molecules with responsibilities ranging from ind filings to latestage development including latestage development of cometriq™ an fdaapproved therapy for the treatment of medullary thyroid cancer earlier in her career dr sacks served as vice president of clinical development at cell genesys a company focused on the development of cancer vaccines and engineered chimeric antigen receptor car t cells prior to her tenure in biotechnology she served in a variety of research and analytical roles at academic institutions and companies including massachusetts general hospital medical college of pennsylvania and icistuart pharmaceuticals in addition to her industry experience dr sacks holds an active faculty appointment at the university of california san francisco where she is an assistant clinical professor of medicine in the division of hematologyoncology she received her md from the university of pennsylvania school of medicine her ms in biostatistics from harvard university school of public health and her ba in mathematics from bryn mawr college gregory w schafer chief operating officer gregory w schafer has served as our chief operating officer since july  prior to joining aduro he served as chief financial officer of jennerex biotherapeutics acquired by sillajen a privately held biotechnology company from june  to july  where he was responsible for finance accounting planning investor relations and treasury functions from april  to january  he served as chief financial officer of onyx pharmaceuticals acquired by amgen where he was responsible for finance accounting risk management and strategic and operational planning earlier in his career mr schafer served as chief financial officer and vice president of finance for intrabiotics pharmaceuticals and cerus corporation prior to entering the field of biotechology he worked as a management consultant for deloitte  touche llp he received his mba from the anderson graduate school of management at the university of california los angeles and a bse in mechanical engineering from the university of pennsylvania hans van eenennaam phd chief operational officer aduro biotech europe hans van eenennaam phd became chief operational officer of aduro biotech europe in november  prior to its acquisition by aduro in  dr van eenennaam served as chief operational officer of bionovion a company he cofounded in  to focus on the development of innovative therapeutic antibodies in the field of immune oncology  earlier in his career he held numerous positions of increasing responsibility at organon in oss netherlands and the organon research center in cambridge massachusetts which was acquired by scheringplough corporation in  and later by merck  co he led the discovery and development of therapeutic monoclonal antibodies and small molecule entities in the field of oncology and immunology  while at organon dr van eenennaam in cooperation with a team of scientists discovered pembrolizumab keytruda® a humanized therapeutic antibody acquired by merck and approved in  by the us food and drug administration for the treatment of melanoma and subsequently for additional indications including nonsmall cell lung cancer and head and neck cancer  in  he and colleagues were honored by the intellectual property owner’s association with the rd annual inventor of the year award he is named as inventor on seven pending and granted patent families including the patents claiming keytruda and author on over  publications  dr van eenennaam received his doctorate in autoimmune biochemistry cum laude from radboud university in nijmegen netherlands dr andrea van elsas phd chief scientific officer aduro biotech europe andrea van elsas became chief scientific officer of aduro biotech europe in november   prior to its acquisition by aduro in  dr andrea van elsas cofounded bionovion and served as chief scientific officer focusing on the development of innovative therapeutic antibodies in the field of immune oncology  from  to  he held numerous positions at organon in oss netherlands and cambridge massachusetts acquired by scheringplough corporation in  and later by merck  co and as the director of tumor immunology he ran the immune oncology portfolio including the program that later became known as pembrolizumab as a postdoctoral researcher from  andrea worked at the university of california berkeley studying antibodies blocking ctla for the treatment of cancer and is a coinventor on the original patents that formed the basis for the development of yervoy® ipilimumab the first checkpoint inhibitor approved in  by the us food and drug administration for the treatment of melanoma   dirk g brockstedt phd executive vice president research  development dirk g brockstedt phd joined aduro in april  and has served as our senior vice president of research and development since september  prior to joining aduro dr brockstedt held various positions of increasing responsibility in the immunotherapy group at cerus corporation culminating as director of immunology  earlier in his career dr brockstedt worked as a scientist at aventis in the immunotherapy and antiangiogenesis group from  until  focused on developing novel anticancer therapies he has coauthored  scientific papers and is a named inventor on five issued patents and several pending applications dr brockstedt holds a diplomamasters of science in microbiology from the university of kiel and earned his phd from the university of kiel and stanford university the latter at which he served as a postdoctoral fellow at the stanford school of medicine in the department of pathology jennifer lew senior vice president finance jennifer lew joined aduro in october  and has served as our senior vice president of finance since january  prior to joining aduro from  to  ms lew held various positions of increasing responsibility at dynavax technologies culminating as vice president of finance and principal accounting officer responsible for all accounting and finance operations earlier in her career ms lew served as assistant controller and director of finance at qrs corporation a publiclyheld technology company and was a member of the audit practice at ernst  young ms lew earned a ba in economicsaccounting and government from claremont mckenna college and is a certified public accountant inactive status quoc lenguyen senior vice president chemistry manufacturing and control quoc lenguyen joined aduro in september  and has served as our senior vice president of chemistry manufacturing and control cmc since september  he brings over  years of experience in biopharmaceutical operations having held positions of increasing responsibility at both large pharmaceutical and startup companies prior to joining aduro mr lenguyen spent seven years at bayer healthcare as the vice president of technical operations before bayer he served at chiron corporation and novartis ag as director of manufacturing operations earlier in his career he served as senior manager of manufacturing operations at biomarin pharmaceutical where he played an integral role in bringing the company’s lead drug candidate from phase  to commercial launch mr lenguyen holds a bs from university of california davis in biochemistry blaine templeman executive vice president general counsel and secretary blaine templeman joined aduro as executive vice president general counsel and secretary in september  he brings over  years of experience counseling biotechnology companies in the development and commercialization of their products prior to joining aduro mr templeman was a corporate and intellectual property partner at arnold  porter llp where he counseled us and international clients on the protection development and commercialization of their products intellectual property portfolios contract manufacturing clinical trials research and outsourcing his transactional experience includes a variety of collaborations licensing transactions mergers and acquisitions asset sales manufacturing and distribution arrangements and copromotion transactions before arnold  porter llp he was a partner at heller ehrman mr templeman holds a jd from new york university and a bs from oral roberts university sylvia wheeler senior vice president corporate affairs and investor relations sylvia wheeler joined aduro as senior vice president corporate affairs and investor relations in january  she brings over  years of experience in the biopharmaceutical industry having served in a number of executive management roles encompassing investor and media relations as well as corporate and product communications prior to joining aduro ms wheeler served as vice president of investor relations and corporate affairs at relypsa after having served this same role for hyperion therapeutics earlier in her career she was vice president corporate communications at affymax where over a sixyearperiod she supported the company’s transition from a research and development company to a commercial organization with its first marketed product ms wheeler held similar communications roles at depomed cerus corporation and coulter pharmaceutical ms wheeler holds an mba from university of san francisco and a ba in biology from san francisco state university michele devries vice president regulatory affairs michele devries joined aduro in  and currently serves as vice president of regulatory affairs  she is responsible for all aspects of regulatory strategy implementation and oversight of aduro’s proprietary partnered and licensed programs both in the us and internationally prior to aduro ms devries served as director of regulatory affairs for intarcia therapeutics  in this role she managed key regulatory aspects of intarcia’s drug delivery system served as the primary contact for regulatory authorities and was responsible for all aspects of routine and specialized regulatory submissions including preparation for launch of four global phase  studies before intarcia she held escalating regulatory affairs positions at vaxgen intermune and tularik  she received her bs in chemical engineering from the university of minnesota celeste ferber vice president associate general counsel celeste ferber joined aduro in  and currently serves as vice president associate general counsel prior to aduro she was with shearman  sterling llp where she served as counsel in the capital markets group  ms ferber has over  years of experience advising public and private companies on corporate and finance matters including securities offerings mergers acquisitions and strategic transactions corporate governance and securities law compliance before shearman  sterling ms ferber was counsel at morrison  foerster llp working in their palo alto hong kong and san diego offices ms ferber received her jd from the university of california hastings college of law and her ba in economics from bucknell university she is the author of numerous publications regarding legal matters nancy kaplan vice president human resources and facility operations nancy kaplan joined aduro in  and currently serves  as aduro’s vice president of human resources and facility operations prior to aduro ms kaplan worked with a wide variety of small biotech companies applying her broad generalist skill set to establish and bolster finance human resources facility management grant administration and investor relations functions in addition she was marketing communications manager at applied biosystems and supervised biotech accounts at lena chow advertising earlier in her career ms kaplan was part of the founding group at invitron corp a mammalian cell contract manufacturer ms kaplan holds a bs in agronomy from oregon state university anne moon phd vice president project management anne moon phd joined aduro in  and currently serves as vice president of project management prior to aduro dr moon was a founding team member of jennerex biotherapeutics acquired by sillajen where she served as vice president of product development earlier in her career dr moon was part of the startup team at cytokinetics establishing the cellbased screening program and served as project manager of the oncolytic virus program at onyx pharmaceuticals acquired by amgen after completing postdoctoral work within the small molecule therapeutics program targeting small gtpases she received her phd in molecular and cell biology from the university of california berkeley and her ba in biology from harvard university aimee murphy vice president clinical development and operations ms murphy joined aduro in  and currently serves as vice president of clinical development and operations  prior to aduro ms murphy advanced the development of the ladd live attenuated doubledeleted immunotherapy platform at both cerus corporation and anza therapeutics where she managed the first phase  studies that led to aduros existing ladd clinical programs prior to focusing on ladd she worked on the development of prophylactic vaccines and drugs for oncology and infectious diseases at vaxgen coulter pharmaceuticals and shaman pharmaceuticals additionally ms murphy brings experience in quality assurance from bayer pharmaceuticals she holds a bs in biology from pepperdine university justin skoble phd vice president technical operations justin skoble phd joined aduro in  and currently serves as aduro’s vice president of technical operations prior to aduro dr skoble held positions with increasing responsibilities in the molecular biology and process development departments at anza therapeutics and cerus corporation he earned his ba in biology from vassar college and his phd in molecular and cell biology from the university of california berkeley in the laboratory of dr daniel portnoy additionally dr skoble performed postdoctoral work at the university of california san francisco ucsf in the laboratory of dr jeff cox professor of microbiology and immunology at ucsf liana wu vice president commercial liana wu joined aduro in april  as vice president commercial bringing with her over  years of commercial experience in the biotechnology industry and a successful track record in brand development and product launches prior to aduro ms wu spent nine years at onyx pharmaceuticals acquired by amgen where she was most recently vice president oncology franchise while at onyx she was instrumental in overseeing the collaboration with bayer for nexavar and stivarga in the united states  earlier in her career ms wu held several sales and marketing positions at genentech with responsibilities associated with the company’s key oncology brands including rituxan herceptin and tarceva ms wu holds a master’s in public health from the johns hopkins university and a bs in economics from the wharton school at the university of pennsylvania leadership board of directors scientific advisory board culture global headquarters community affairs home about us leadership board of directors scientific advisory board culture global headquarters community affairs pipeline clinical trials access to our investigational agents technology immunotherapy ladd sting pathway bselect antibodies scientific publications intellectual property partnerships media press releases corporate video investors press releases events  presentations corporate governance leadership board of directors committee composition financials  filings financial reports quarterly results analyst coverage stock information stock chart faqs careers contact home about us leadership board of directors scientific advisory board culture global headquarters community affairs pipeline clinical trials access to our investigational agents technology immunotherapy ladd sting pathway bselect antibodies scientific publications intellectual property partnerships media press releases corporate video investors press releases events  presentations corporate governance leadership board of directors committee composition financials  filings financial reports quarterly results analyst coverage stock information stock chart faqs careers contact privacy policy terms and conditions of use   aduro biotechall rights reserved privacy policy terms and conditions of use website design hane chow inc twitterlinkedin